UNSPSC 51422103: Clocortolone

This classification denotes a therapeutic glucocorticoid, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N8ZUB7XE0H. European Medicines Agency schedules Clocortolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06686MIG. Clocortolone generally arises in the molecular formula C22H28CLFO4.

UNSPSC 51422103 Clocortolone, a Commodity code, nominally describes a specific topical corticosteroid active pharmaceutical ingredient, but the recent state and local opportunities tagged under it involve naloxone (an opioid antagonist) and safe drug deactivation systems, indicating a mismatch between the code's nominal scope and what procurement offices are actually buying under it. The Seminole County, Florida IFB solicits 1,900 units of naloxone and 800 safe drug deactivation systems annually for community health initiatives, while the Texas Health and Human Services Commission issued a Request for Information to explore direct-to-manufacturer prescription fulfillment programs outside traditional pharmacy benefit manager arrangements. These divergent procurements—one a narrow commodity purchase with quarterly delivery cycles, the other a strategic market-intelligence initiative—do not align cleanly with the code's pharmaceutical ingredient definition, suggesting the code may be misapplied in state and local systems or that the tagging reflects a broader pharmaceutical supply classification rather than the specific drug substance the code names.

Issuing bodies using this code include county health departments and state health agencies; Seminole County and the Texas Health and Human Services Commission are the only recent sources named. Geographic activity centers on Florida and Texas as of mid-2026. The Seminole County opportunity (IFB 60459723LAS, due July 26, 2023, with electronic submission through the county's e-Procurement Portal) requires unit pricing for naloxone and deactivation systems, drug-free workplace certification, E-Verify compliance, and includes a three-month probationary termination clause; the contract carries a two-year initial term with one-year renewal options and potential FEMA funding with associated federal environmental compliance requirements. The Texas HHS RFI (HHS0017013, posted April 3, 2026) is exploratory rather than transactional, seeking vendor input on direct contracting models with manufacturers outside PBM and GPO intermediaries, with no award value, budget, or binding timeline specified. Given the mismatch between code scope and actual procurement content, activity under this code shows limited relevance to clocortolone-specific pharmaceutical suppliers.